Recent data published in PLOS ONE demonstrate that ImmuSmol’s anti-L-Kynurenine antibody can serve to stratify cancer patients for kynurenine pathway activity. Among key findings, data collected from human colorectal and breast cancer tissues highlights that IDO1 expression does not strictly match L-Kynurenine production. The article thus suggests that in situ detection of L-Kynurenine constitutes a powerful biomarker of IDO-1/-2 or TDO2 activity.

Useful links:

>>> Open-access PLOS ONE article

>>> L-Kynurenine monoclonal antibody